KYNTRA BIO, INC. Operating Cash Flow
KYNTRA BIO, INC. (KYNB) reported Operating Cash Flow of -$17.88 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- KYNTRA BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$3.99M, a 131.47% decline year-over-year.
- KYNTRA BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$13.89M, a 610.74% decline year-over-year.
- KYNTRA BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$18.33M.
- KYNTRA BIO, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$1.85M.
- KYNTRA BIO, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$4.77M.
- KYNTRA BIO, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$138.00M.
- KYNTRA BIO, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$315.02M.
- KYNTRA BIO, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$145.93M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$17.88M 10-Q · filed 2026-08-13 | -$36.21M derived: sum of 3 quarters · filed 2026-08-13 | -$38.05M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$13.89M 10-Q · filed 2026-05-12 | -$32.22M derived: sum of 2 quarters · filed 2026-05-12 | -$34.06M derived: sum of 3 quarters · filed 2026-05-12 | -$21.38M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$18.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$20.18M derived: sum of 2 quarters · filed 2026-03-16 | -$7.49M derived: sum of 3 quarters · filed 2026-08-13 | -$4.77M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$1.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $10.84M derived: sum of 2 quarters · filed 2026-08-13 | $13.55M 10-Q · filed 2025-11-10 | -$16.91M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $12.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $15.40M 10-Q · filed 2026-08-13 | -$15.06M derived: sum of 3 quarters · filed 2026-08-13 | -$23.44M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.72M 10-Q · filed 2026-05-12 | -$27.75M derived: sum of 2 quarters · filed 2026-05-12 | -$36.12M derived: sum of 3 quarters · filed 2026-05-12 | -$75.99M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$30.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$38.84M derived: sum of 2 quarters · filed 2026-03-16 | -$78.71M derived: sum of 3 quarters · filed 2026-03-16 | -$138.00M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$8.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$48.24M derived: sum of 2 quarters · filed 2025-11-10 | -$107.53M 10-Q · filed 2025-11-10 | -$125.85M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$39.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$99.16M 10-Q · filed 2025-08-11 | -$117.48M derived: sum of 3 quarters · filed 2025-08-11 | -$202.02M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$59.29M 10-Q · filed 2025-05-12 | -$77.61M derived: sum of 2 quarters · filed 2025-05-12 | -$162.15M derived: sum of 3 quarters · filed 2025-05-12 | -$272.72M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$18.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$102.86M derived: sum of 2 quarters · filed 2025-03-17 | -$213.43M derived: sum of 3 quarters · filed 2025-03-17 | -$315.02M 10-K · filed 2025-03-17 |
| 2023-09-30 | -$84.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$195.11M derived: sum of 2 quarters · filed 2024-11-12 | -$296.70M 10-Q · filed 2024-11-12 | -$349.21M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$110.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$212.16M 10-Q · filed 2024-08-06 | -$264.68M derived: sum of 3 quarters · filed 2024-08-06 | -$316.56M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$101.59M 10-Q · filed 2024-05-06 | -$154.10M derived: sum of 2 quarters · filed 2024-05-06 | -$205.98M derived: sum of 3 quarters · filed 2024-05-06 | -$239.05M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | -$52.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$104.39M derived: sum of 2 quarters · filed 2024-02-26 | -$137.46M derived: sum of 3 quarters · filed 2024-02-26 | -$145.93M 10-K · filed 2024-02-26 |
| 2022-09-30 | -$51.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$84.94M derived: sum of 2 quarters · filed 2023-11-06 | -$93.42M 10-Q · filed 2023-11-06 | -$148.38M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$33.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$41.54M 10-Q · filed 2023-08-07 | -$96.50M derived: sum of 3 quarters · filed 2024-02-26 | -$52.24M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | -$8.48M 10-Q · filed 2023-05-08 | -$63.44M derived: sum of 2 quarters · filed 2024-02-26 | -$19.18M derived: sum of 3 quarters · filed 2024-02-26 | -$45.72M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | -$54.96M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$10.71M derived: sum of 2 quarters · filed 2024-02-26 | -$37.25M derived: sum of 3 quarters · filed 2024-02-26 | -$82.23M 10-K · filed 2024-02-26 |
| 2021-09-30 | $44.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $17.71M derived: sum of 2 quarters · filed 2022-11-07 | -$27.27M 10-Q · filed 2022-11-07 | -$34.50M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$26.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$71.53M 10-Q · filed 2022-08-08 | -$78.75M derived: sum of 3 quarters · filed 2023-02-27 | -$80.10M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$44.98M 10-Q · filed 2022-05-09 | -$52.21M derived: sum of 2 quarters · filed 2023-02-27 | -$53.56M derived: sum of 3 quarters · filed 2023-02-27 | $96.10M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$7.23M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$8.58M derived: sum of 2 quarters · filed 2023-02-27 | $141.09M derived: sum of 3 quarters · filed 2023-02-27 | $81.60M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$1.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $148.32M derived: sum of 2 quarters · filed 2021-11-09 | $88.83M 10-Q · filed 2021-11-09 | $43.78M derived: sum of 4 quarters · filed 2022-03-04 |
| 2020-06-30 | $149.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $90.18M 10-Q · filed 2021-08-09 | $45.13M derived: sum of 3 quarters · filed 2022-03-04 | $17.65M derived: sum of 4 quarters · filed 2022-03-04 |
| 2020-03-31 | -$59.49M 10-Q · filed 2021-05-10 | -$104.54M derived: sum of 2 quarters · filed 2022-03-04 | -$132.02M derived: sum of 3 quarters · filed 2022-03-04 | -$160.67M derived: sum of 4 quarters · filed 2022-03-04 |
| 2019-12-31 | -$45.05M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-04 | -$72.53M derived: sum of 2 quarters · filed 2022-03-04 | -$101.19M derived: sum of 3 quarters · filed 2022-03-04 | -$78.70M 10-K/A · filed 2022-03-04 |
| 2019-09-30 | -$27.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$56.13M derived: sum of 2 quarters · filed 2020-11-05 | -$33.66M 10-Q · filed 2020-11-05 | -$51.12M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$28.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$6.17M 10-Q · filed 2020-08-06 | -$23.64M derived: sum of 3 quarters · filed 2021-03-01 | -$15.39M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $22.48M 10-Q · filed 2020-05-07 | $5.01M derived: sum of 2 quarters · filed 2021-03-01 | $13.26M derived: sum of 3 quarters · filed 2021-03-01 | -$21.70M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$17.46M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$9.22M derived: sum of 2 quarters · filed 2021-03-01 | -$44.18M derived: sum of 3 quarters · filed 2021-03-01 | -$76.14M 10-K · filed 2021-03-01 |
| 2018-09-30 | $8.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$26.72M derived: sum of 2 quarters · filed 2019-11-12 | -$58.68M 10-Q · filed 2019-11-12 | -$59.87M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | -$34.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$66.93M 10-Q · filed 2019-08-08 | -$68.11M derived: sum of 3 quarters · filed 2020-03-02 | -$86.55M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$31.96M 10-Q · filed 2019-05-09 | -$33.15M derived: sum of 2 quarters · filed 2020-03-02 | -$51.58M derived: sum of 3 quarters · filed 2020-03-02 | |
| 2017-12-31 | -$1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$19.62M derived: sum of 2 quarters · filed 2020-03-02 | -$66.51M 10-K · filed 2020-03-02 | |
| 2017-09-30 | -$18.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$65.33M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | -$46.89M 10-Q · filed 2018-08-07 | |||
| 2016-12-31 | $7.11M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |